Immune Pharmaceuticals(美國)

Immune Pharmaceuticals

ImmunePharmaceuticalswww.immunepharmaceuticals.com關(guān)注于治療炎癥疾病與癌癥的抗體治療平臺(tái)ImmunePharmaceuticalsInc.(NASDAQOMXStockholmExchange:IMNP;OTCQX:IMNP,formerlyEPCTD)appliesapersonalizedapproachtotreatment,developi ngnovel,highlytargetedantibodytherapeuticstoimprovethelivesofpatientswithinflammatorydiseasesandcancer.TheCompany'sleadproductcandidate,bertilimumab,isenteringPhaseIIclinicalstudiesformoderate-to-severeulcerativecolitisandbullouspemphigoid,withadditionalstudiesplannedforCrohn'sdiseaseandsevereasthma.TheCompanyisevaluatingtheuseofitsNanomAb®platform,asecondgenerationantibodydrugconjugatetechnology,withchemotherapeuticsinordertoenhancetheirsafetyandefficacyprofilesbydeliveringthemedicinesdirectlytocancercells.TheCompany'sgrowingoncologypipelinealsoincludesproprietaryantibodiesand,clinical-stagesmallmoleculesthathavebeenshownactivityinavarie